Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs British American Tobacco PLC (BTI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs British American Tobacco PLC — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while British American Tobacco PLC trades at $59.05 (market cap $127.15B). The key difference: British American Tobacco PLC is far larger — about 3.2× Alnylam Pharmaceuticals, Inc.'s market cap, and British American Tobacco PLC pays a 5.56% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BTI | |
|---|---|---|
Market Cap | $39.89B | $127.15B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $66.70 |
52-Week Low | $278.09 | $50.39 |
Enterprise Value | $38.15B | $168.38B |
Dividend Yield | — | 5.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
British American Tobacco (BTI) trades at $60.02, down 1.4% on the day, with a bearish technical signal from moving averages. The company shows strong profitability with a net income margin of 30.32% and a P/E ratio of 13.02, indicating potential undervaluation. Recent earnings have mostly beaten expectations, and the firm maintains a robust dividend, with two $0.83 payouts scheduled for H2 2026. However, 2023 saw a significant net loss, and 2025 cash flow is projected negative, highlighting volatility.
BTI offers a compelling value proposition with high margins and analyst support (66.7% buy ratings), but faces headwinds from regulatory pressures, declining cigarette volumes, and restructuring costs. The stock's outlook balances income appeal against sector-specific risks, requiring careful monitoring of its transition to smoke-free products and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →
